VativoRx Joins MHA: A New Chapter Begins

VativoRx Joins MHA: A New Chapter Begins

The world of healthcare is dynamic, continuously evolving with new challenges and opportunities. At VativoRx, we’ve always believed in the power of innovation, collaboration, and dedication to ensure that we provide the best rebate management solutions in the industry. Today, we’re thrilled to announce our latest milestone: VativoRx is now an official associate member of the Michigan Health & Hospital Association (MHA)!

Leading the Way in Rebate Management

For over eight years, we’ve been at the forefront of rebate management. Our commitment to data integrity, compliance, and security has been unwavering. We pride ourselves on maintaining the highest standards of professional and ethical conduct, ensuring our partners and clients receive unparalleled service.

More Than Just Service Providers

VativoRx is not just another service provider in the vast healthcare landscape. We envision ourselves as partners. As we join the MHA community, our objective is to further solidify our commitment to the healthcare community in Michigan. Together, we aim to ensure operational excellence, financial robustness, and a brighter future for healthcare facilities across the state.

Driving Unparalleled Value

Our comprehensive approach guarantees that healthcare facilities have the opportunity to maximize their rebate revenues and achieve significant financial gains. With our dedicated team, innovative solutions, and a passion for excellence, we are here to deliver tangible results.

Looking Ahead

As we embark on this exciting new journey with MHA, we’re optimistic about the possibilities that lie ahead. We’re eager to work closely with other MHA members, share insights, learn from one another, and collectively drive the healthcare industry forward.

For more details about our collaboration and how VativoRx is shaping the future of rebate management, check out the official announcement here.

Stay tuned for more updates and insights from VativoRx. Together, we’re making healthcare better, one step at a time.

Martin Shields / Alamy Stock Photo

Humira – The End of an Era

In January 2023, the first biosimilar version of Humira, which is a widely used injectable drug for inflammatory diseases, was approved, marking the end of AbbVie’s two-decade market exclusivity. Humira is used to treat conditions like rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, and it works by targeting certain proteins in the immune system.

Read More »

Biosimilars — Similar But Not Identical

You may have never heard of biosimilar drugs and that’s probably because they are not commonly prescribed in the United States even though they have been around for over 20 years. So, what are biosimilar drugs? A biosimilar drug is no different in terms of safety and effectiveness than a biologic product, also known as a reference product, and while highly similar it is not identical.

Read More »

Lower Cost Prescription Drugs from Canada, Is It Legal?

In the early 2000s, the FDA set up guidelines in the Regulatory Procedures Manual (RPM) that permitted prescription drugs to be imported from other countries if the patient met very strict guidelines. Just stating that the patient needed the drug due to cost savings was not a justification to obtain the drug.

Read More »